InterventiOnal Study of Bone and Joint Infections Related Gut dysbiosIS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-31

Study Completion Date

2018-03-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Gut dysbiosis is an intestinal disorder that is characterized by accumulation of microbiota imbalance, host-microbiota crosstalk dysfunction and inflammation.

As part of its clinical development, MaaT (Microbiota as a Therapy) Pharma is particularly interested in patients with Bone and Joint Infections (BJI). These patients are treated with antibiotics having significant consequences on their intestinal flora, causing intestinal discomfort, which can be manifested by diarrhea.

MaaT Pharma wishes to carry out a clinical study, OSIRIS, in collaboration with Prof. Tristan Ferry, member and coordinator of CRIOAc (Centre de Référence des Infections Ostéo-Articulaires Complexes) Lyon, Center of Reference of Bone and Joint Infections (BJI). The objective of this study is to follow patients with treated BJI in order to characterize intestinal dysbiosis and the future relevance of an autologous Fecal Microbiota Transplantation (aFMT) intervention.

To do this, patients will be monitored according to the current CRIOAc recommendations, with the aim of taking biological samples from patients at the same time as scheduled visits, routine monitoring patients. Only one additional consultation will be carried out 15 days after stopping the antibiotics in order to better evaluate the dysbiosis evolution.

Thus biological samples (blood, stool, nasal, rectal) will be taken during the follow-up consultations over a period of 6 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Osteomyelitis Multi-center Prospective Cohort Study

NCT07251374

Osteomyelitis of Lower Extremities

NOT_YET_RECRUITING

Analysis of DNA Methylation in Spondyloarthritis

NCT03092583

Spondylitis, Ankylosing Axial Spondyloarthritis DNA Methylation

COMPLETED NA

Gut Microbiota in Patients With Moyamoya Disease

NCT04890782

Moyamoya Disease Gut Microbiota

UNKNOWN

Linking Diet, Inflammation, Gut Microbiota, and Sarcopenia: A Cross-Sectional Study

NCT07211321

Sarcopenia

RECRUITING

Role of the Host Microbiota and Il-17 in Favoring Multiple Myeloma Progression

NCT05712967

Multiple Myeloma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bone and Joint Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental arm

Group Type EXPERIMENTAL

Biological samples collection of blood and feces

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biological samples collection of blood and feces

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Consenting subjects with BJI (native or material related BJI) at participating sites who are being treated with antibiotics as part of their standard treatment procedure will be enrolled
* The subject is willing, able to understand and comply to the protocol requirement
* More than 18-years-old
* Subject is suspected for implanted or native BJI and is eligible for antibiotics treatment
* Subject signed Inform Consent Form

Exclusion Criteria

* Pregnancy
* Severe disease with a life expectancy \< 3 months
* Antibiotherapy in the 14 days before inclusion in the study
* Patient non-affiliated to health care system
* Patient under the power of law
* Guardianship, curators patients

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No